Skip to content
Search

Latest Stories

Staffing crisis risks derailing attempts to solve hospital backlog, MPs warn

Attempts to deal with record waiting lists for hospital treatment caused by the Covid-19 pandemic are at risk of being derailed by a staffing crisis, which is being exacerbated by the Omicron wave, a cross-party lawmakers' report said on Thursday (January 6).

The report entitled ‘Clearing the backlog caused by the pandemic’ calls for a broader national health and care recovery plan -- one that would embrace A&E, mental health, GPs, community and social care.


Hospitals are facing extreme pressure as they try to catch up on months of operations that have been delayed and suspended during the pandemic, as Covid-19 hospitalizations rise once more and self-isolation hits staffing levels.

There is a record 5.8 million waiting list for elective care, the Health and Social Care Committee said, adding that a recent surge in the Omicron variant has pushed cases to record highs and intensified pre-existing issues.

"Our report finds that the government's recovery plans risk being thrown off course by an entirely predictable staffing crisis," committee chair Jeremy Hunt said, adding there was no clear plan to address a burnt-out workforce and 93,000 vacancies in the NHS.

"Far from tackling the backlog, the NHS will be able to deliver little more than day to day firefighting unless the government wakes up to the scale of the staffing crisis facing the NHS, and urgently develops a long-term plan to fix the issue."

The committee urged the health ministry to work with the state-run NHS to produce a recovery plan by April.

Prime minister Boris Johnson has warned that Omicron will make the next few weeks challenging, and that there will be staffing disruptions, as he aims to ride out the wave of infections without further restrictions in England.

With waiting times in October 2021 already the worst since records began, the committee said that there should be an independent assessment of the NHS workforce at least every 2 years to ensure enough doctors and nurses are being trained.

Report calls for robust workforce planning: RPS

Commenting on the report, chair of the Royal Pharmaceutical Society in England Thorrun Govind said: “Pharmacists and pharmacy teams across the health service have shown enormous dedication to patient care throughout the pandemic. This latest committee report highlights once again the urgent need for robust workforce planning and support.

“With winter pressures and a spike in Covid-related staff absences, this also means prioritising essential work, cutting unnecessary bureaucracy, and ensuring pharmacists can take adequate rest breaks. The pandemic has shown just how important it is that the Government and NHS support collaboration across health professions to maintain patient access to care.

"If we are to clear the immediate backlog of care from the pandemic and support the NHS recovery in the longer-term, then we must see investment in pharmacy as part of a comprehensive workforce strategy.”

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less